Novo Nordisk A/S - Share repurchase programme

Udgivet den 30-05-2016  |  kl. 13:27  |  

Bagsværd, Denmark, 30 May 2016 - On 3 February 2016, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 14 billion to be executed during a 12-month period beginning 3 February 2016.

Under the programme initiated 29 April 2016, Novo Nordisk will repurchase B shares for an amount up to DKK 3.5 billion in the period from 29 April 2016 to 3 August 2016.

Since the announcement as of 19 May 2016, the following transactions have been made under the programme:

  Number of
B shares
Average
purchase price
Transaction
value, DKK
Accumulated, last announcement 1,642,000   587,842,892
19 May 2016 160,000 358.51 57,362,224
20 May 2016 158,000 359.30 56,768,768
23 May 2016 145,000 356.92 51,753,226
24 May 2016 150,000 361.06 54,158,385
25 May 2016 145,000 375.17 54,400,201
26 May 2016 150,000 373.18 55,977,090
27 May 2016 140,000 371.46 52,004,610
Accumulated under the programme 2,690,000   970,267,396

With the transactions stated above, Novo Nordisk owns a total of 14,767,645 B shares of DKK 0.20, corresponding to 0.6% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,550,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 14 billion during a 12-month period beginning 3 February 2016. As of 27 May 2016, Novo Nordisk has repurchased a total of 12,836,000 B shares equal to a transaction value of DKK 4,599,822,121.

Further information

Media:    
Anne Margrethe Hauge +45 3079 3450 amhg@novonordisk.com
Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com
     
Investors:    
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com
Kasper Veje (US) +1 609 235 8567 kpvj@novonordisk.com
     


Company announcement no 43 / 2016


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire

HUG#2016462

\Hugin

Udgivet af: NPinvestordk